Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites
medicalxpress - Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial si…
AI Summary: A new analysis shows Phase I lung cancer trials are becoming concentrated at a relatively small number of leading U.S. centers, raising concerns about geographic inequity in access to early‑phase studies. The trend could speed drug development at elite sites while leaving patients in other regions with fewer experimental options and longer travel burdens.
- Conference highlights, care models and awareness (4)
- Consolidation at top U.S. Phase I centers (3)
- Early-phase trials and next-gen therapies (4)
- All Other Stories
Conference highlights, care models and awareness
Consolidation at top U.S. Phase I centers
Early-phase trials and next-gen therapies
All Other Stories
Related Stories
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days
Teclistamab shows survival benefit prompting earlier use discussions / 21 days
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 2 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 2 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 2 months
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 3 months
ELCC 2026 showcases lung-cancer trials, new data, and collaborations / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Alzheimer's disease, Biotech, FDA, Reproductive Health and look for the RSS link.
StackHealth Time Machine